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Background: Helicobacter pylori (H. pylori) infection and excessive salt intake are known as important risk factors for
stomach cancer in humans. However, interactions of these two factors with gene expression profiles during gastric
carcinogenesis remain unclear. In the present study, we investigated the global gene expression associated with
stomach carcinogenesis and prognosis of human gastric cancer using a mouse model.
Methods: To find candidate genes involved in stomach carcinogenesis, we firstly constructed a carcinogen-induced
mouse gastric tumor model combined with H. pylori infection and high-salt diet. C57BL/6J mice were given
N-methyl-N-nitrosourea in their drinking water and sacrificed after 40 weeks. Animals of a combination group were
inoculated with H. pylori and fed a high-salt diet. Gene expression profiles in glandular stomach of the mice were
investigated by oligonucleotide microarray. Second, we examined an availability of the candidate gene as
prognostic factor for human patients. Immunohistochemical analysis of CD177, one of the up-regulated genes, was
performed in human advanced gastric cancer specimens to evaluate the association with prognosis.
Results: The multiplicity of gastric tumor in carcinogen-treated mice was significantly increased by combination of
H. pylori infection and high-salt diet. In the microarray analysis, 35 and 31 more than two-fold up-regulated and
down-regulated genes, respectively, were detected in the H. pylori-infection and high-salt diet combined group
compared with the other groups. Quantitative RT-PCR confirmed significant over-expression of two candidate
genes including Cd177 and Reg3g. On immunohistochemical analysis of CD177 in human advanced gastric cancer
specimens, over-expression was evident in 33 (60.0%) of 55 cases, significantly correlating with a favorable
prognosis (P = 0.0294). Multivariate analysis including clinicopathological factors as covariates revealed high
expression of CD177 to be an independent prognostic factor for overall survival.
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Conclusions: These results suggest that our mouse model combined with H. pylori infection and high-salt diet is
useful for gene expression profiling in gastric carcinogenesis, providing evidence that CD177 is a novel prognostic
factor for stomach cancer. This is the first report showing a prognostic correlation between CD177 expression and
solid tumor behavior.
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Stomach cancer is the fourth most common cancer and
second leading cause of cancer-related death worldwide
[1]. Helicobacter pylori (H. pylori) is now recognized as a
major risk factor for chronic gastritis and stomach cancer
development [2]. In addition, environmental and host fac-
tors have also been shown to influence gastric carcinogen-
esis, and salt (sodium chloride, NaCl) and salty food are of
particular importance, based on evidence from a number
of epidemiological and experimental studies [3-6]. Thus,
combined exposure to H. pylori infection and excessive
salt intake appears to be very important for the develop-
ment and progression of gastric tumors, although the de-
tailed mechanisms, especially in terms of gene expression
profiles, remain to be clarified.
High throughput microarray technology provides a
powerful tool for comprehensive gene analysis, already ap-
plied to assess gene expression patterns in both human
samples and animal models of gastric disorders [7-16]. Al-
though many researchers have focused on gene expression
in H. pylori-treated gastric cell lines [17-19], results in cell
culture do not necessarily correlate with expression of spe-
cific genes in the in vivo microenvironment featuring host
immune responses and stromal-epithelial interactions in
cancers. Carcinogen-treated Mongolian gerbils have been
used as a useful animal model of H. pylori-associated gas-
tric carcinogenesis [20-24], and we previously reported that
a synergistic interaction between H. pylori infection and
high-salt intake accelerates chronic inflammation and
tumor development in the stomachs of these animals
[25,26]. Unfortunately, there is little information available
for the gerbil genome, hampering genetic and molecular
analysis. Therefore, attention has focused on mouse
models [12,13], and establishment of a mouse model for
stomach cancer featuring salt and H. pylori exposure is
needed for investigations targeting genes involved in gas-
tric carcinogenesis.
Previous microarray studies using rodent models did
not distinguish and characterize expression profiles based
on the interaction of H. pylori infection and salt intake. In
the present study, we examined gene expression in the
gastric mucosa in a H. pylori-infected and high-salt diet-
treated mouse gastric tumor model by oligonucleotide
microarray and found two candidate up-regulated genes
including Cd177 and Reg3g. We also investigated theexpression of CD177 in human advanced gastric cancers
by immunohistochemistry, and obtained evidence as a po-
tential prognostic factor for stomach carcinogenesis.
Methods
Inoculation with H. pylori
H. pylori was prepared by the same method as described
previously [27,28]. Briefly, H. pylori (Sydney strain 1) was
inoculated on Brucella agar plates (Becton Dickinson,
Cockeysville, MD, USA) containing 7% (v/v) heat-
inactivated fetal bovine serum (FBS) and incubated at 37°C
under microaerophilic conditions at high humidity for
2 days. Then, bacteria grown on the plates were introduced
into Brucella broth (Becton Dickinson) supplemented with
7% (v/v) FBS and incubated under the same conditions for
24-h. After 24-h fasting, animals were intra-gastrically inoc-
ulated H. pylori (1.0 × 108 colony-forming units). Before in-
oculation, the broth cultures of H. pylori were checked
under a phase-contrast microscope for bacterial shape and
mobility.Animals and experimental protocol
Fifty-six specific pathogen-free male, 5- or 6-week-old
C57BL/6J mice (CLEA Japan, Tokyo, Japan) were used in
this study. All animals were housed in plastic cages on
hardwood-chip bedding in an air-conditioned biohazard
room with a 12-h light/12-h dark cycle, and allowed free
access to food and water throughout. The experimental de-
sign was approved by the Animal Care Committee of the
Aichi Cancer Center Research Institute, and the animals
were cared for in accordance with institutional guidelines
as well as the Guidelines for Proper Conduct of Animal
Experiments (Science Council of Japan, June 1st, 2006).
The experimental design is illustrated in Figure 1A. The
mice were divided into 4 groups (Groups A-D); 21, 5, 15,
and 15 mice were assigned to A, B, C, and D groups, re-
spectively, at the commencement of the experiment. Ani-
mals of Groups B and D were inoculated with H. pylori
intra-gastrically on alternate weeks (total 7 times), while
mice of the other groups were inoculated with Brucella
broth alone. All mice were given N-methyl-N-nitrosourea
(MNU, Sigma Chemical, St Louis, MO, USA) in their
drinking water at the concentration of 120 ppm on alter-
nate weeks (total exposure was 5 weeks). For this purpose
Figure 1 Experimental design and histopathological findings. A: Experimental design. Five- to six-week-old male C57BL/6J mice were
inoculated with H. pylori SS1 strain (Groups B and D) or Brucella broth (Groups A and C). All animals were administered 120 ppm MNU in their
drinking water on alternate weeks (total exposure, 5 weeks). Mice of Groups C and D were given basal diet (CE-2) containing 10% NaCl. B:
Histopathological findings for MNU-induced mice gastric tumors. (a and b) Gastric adenoma in the pyloric region of an MNU-treated and H.
pylori-infected mouse (Group B). (c and d) Gastric adenocarcinoma observed in Group B. Note the high cell density and cellular and structural
atypia. Bar = 200 (a and c) or 100 μm (b and d).
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per week. Mice of Groups C and D received CE-2 diets
(basal sodium content of 0.36%; CLEA Japan) containing
10% NaCl. During the exposure period, one animal of
Group B, one of Group C and six of Group D died or be-
came moribund and they were excluded from the experi-
ment. At 40 weeks, the remained animals were subjected
to deep anesthesia and laparotomy with excision of the
stomach.
Histological evaluation
For histological examination, the stomachs were fixed in
10% neutral-buffered formalin for 24-h, sliced along the
longitudinal axis into strips of equal width, and embedded
in paraffin. Four-μm thick sections were prepared and
stained with hematoxylin and eosin (H&E) for histological
observation. Tumors were classified into adenoma and
adenocarcinoma based on cellular and morphological
atypia and invasive growth to submucosa as we reported
previously [21].
RNA preparation and oligonucleotide microarray analysis
Total RNA was extracted from the whole gastric mucosa
including both tumor and peripheral tissue using an
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) and its
quality checked with a microchip electrophoresis system
(i-chip SV1210; Hitachi Chemical, Tokyo, Japan). High-
quality samples were selected, and pooled for each group
to avoid individual difference for oligonucleotide micro-
array assessment (Group A, n = 3; B, n = 4; C, n = 6; D,
n = 7). The CodeLink Mouse Whole Genome Bioarray
(Applied Microarrays, Tempe, AZ, USA) containing
35,587 probe sets per chip was used to analyze gene ex-
pression profiles. Hybridization, processing, and scan-
ning were performed by Filgen, Inc. (Nagoya, Japan),
scan data images being analyzed using a softwarepackage (Microarray Data Analysis Tool, Filgen).
Complete-linkage hierarchical clustering was also exam-
ined on the four groups using a qualified probe subset
(Filgen).
Quantitative real-time RT-PCR of expression profiles in
mice stomach
Relative quantitative real-time RT-PCR was performed
using a StepOne Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) with the mouse-specific
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) gene
as an internal control. After DNase treatment, first strand
cDNAs were synthesized from total RNA using a Super-
Script VILO cDNA Synthesis Kit (Invitrogen, Carlsbad,
CA, USA). The PCR was accomplished basically following
the manufacturer's instructions using a QuantiTect SYBR
Green PCR Kit (Qiagen). The primer sequences for each
gene are listed in Table 1. Specificity of the PCR reactions
was confirmed using a melt curve program provided with
the StepOne software and electrophoresis of the PCR sam-
ples in 3% agarose gels. The expression levels of mRNAs
were normalized to the mRNA level of Gapdh and com-
pared with the control mice (Group A) by the ΔΔCT
method.
Patients and tumor specimens
A total of 55 cases of primary advanced gastric cancer, sur-
gically resected at Aichi Cancer Center Hospital (Nagoya,
Japan) between 1995 and 2002, were investigated after
obtaining informed consent. The study was approved by
the ethics committee of Aichi Cancer Center. The patients
were all male and the mean age and median follow-up
period were 58.6 ± 10.2 years and 83 weeks, respectively.
None had received preoperative chemotherapy or radio-
therapy. Carcinomas with adjacent mucosa tissue were
fixed and embedded in paraffin, and sectioned for staining
Table 1 Primer sequences for relative quantitative real-time RT-PCR
Gene Sequences Product length Accession no.
Gapdh 5′-AACGGATTTGGCCGTATTG-3′ 140 NM_008084
5′-TTGCCGTGAGTGGAGTCATA-3′
Cd177 5′-AGGGGTGCCACTCACTGTTA-3′ 128 NM_026862
5′-CCGATTGTTTTGGAGTCACC-3
Reg3g 5′-GTATGGATTGGGCTCCATGA-3′ 106 NM_011260
5′-GATTCGTCTCCCAGTTGATG-3′
Muc13 5′-CCTAATCCCTACGCAAACCA-3′ 124 NM_010739
5′-TCTGCCCATTTCTCCTTGTC-3′
Gapdh glyceraldehyde-3-phosphate dehydrogenase, Reg3g regenerating islet-derived protein 3 gamma, Muc13 mucin 13.
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sis of advanced cases were made according to the Japa-
nese Classification of Gastric Carcinomas [29]. The
cancers had invaded the muscularis propria (T2 for
TNM classification), the subserosa (T3), or the serosa
and the peritoneal cavity (T4a), sometimes involving
adjacent organs (T4b).Immunohistochemistry using human gastric cancer tissue
We examined expression of CD177, for which a commer-
cial primary antibody was available, in human gastric can-
cer tissues by immunohistochemistry. After inhibition of
endogenous peroxidase activity by immersion in 3%
hydrogen peroxide/methanol solution, antigen retrieval
was carried out with 10 mM citrate buffer (pH 6.0) in a
microwave oven for 10 min at 98°C. Then, sections were
incubated with a mouse monoclonal anti-CD177 antibody
(clone 4C4, diluted 1:100, Abnova, Taipei, Taiwan). Stain-
ing for CD177 was performed using a Vectastain Elite
ABC Kit (Vector Laboratories, Burlingame, CA, USA) and
binding visualized with 0.05% 3,3′-diaminobenzidine. The
results of CD177 immunostaining in neoplastic cells were
classified into four degrees; grade 0 (none, 0-10% of posi-
tive cells), grade 1 (weak, 10-30%), grade 2 (moderate, 30-
60%), and grade 3 (strong, over 60%) based on proportion
of stained cells, and cases showing moderate to strong
staining were considered as positive.Table 2 Incidence and multiplicity of gastric tumors in MNU-t
Group Effective number Treatment
Adenoma
A 21 MNU 3(14.3)
B 4 MNU + H. pylori 4(100)b
C 14 MNU + 10% NaCl 2(14.3)
D 9 MNU + H. pylori + 10% NaCl 4(44.4)
Values for multiplicity are expressed as means ± SD. Incidences were generally asse
correction. Multiplicities were generally analyzed by ANOVA, followed by the Tukey
cP < 0.05 vs. Group A, dP < 0.05 vs. Group C, eP <0.05 vs. Group B.Statistical analysis
The Chi-square test with Bonferroni correction was used
to assess incidences of gastric tumor. Quantitative values
including multiplicity of tumor and relative expression of
mRNA were represented as means ± SD or SE, and differ-
ences between means were statistically analyzed by
ANOVA or the Kruskal-Wallis test followed by the Tukey
test for multiple comparisons. Overall survival was esti-
mated using the Kaplan-Meier method and the log-rank
test for comparisons. Correlations between CD177 expres-
sion and clinicopathological factors were analyzed by
ANOVA or Chi-square test. Multivariate analysis was
performed to examine whether CD177 over-expression
was an independent prognostic factor using the Cox
proportional-hazards regression model. P values of < 0.05
were considered to be statistically significant.Results
Incidences and multiplicities of gastric tumors
The effective number of mice and the observed incidences
and multiplicities of gastric tumors are summarized in
Table 2. Tumors developed in the gastric mucosa of all
MNU-treated groups (Groups A-D) (Figure 1B). In high-
salt diet-treated groups (Groups C and D), the incidence
of gastric tumor in Group D (H. pylori-infected; 100%)
was significantly higher than that in Group C (non-
infected; 50.0%) (P < 0.05). In basal diet groups (Groups Areated mice
Incidence (%) Multiplicity (no. of tumor/mouse)
Carcinoma Total tumor Adenoma Carcinoma Total tumor
13(61.9) 13(61.9) 0.1 ± 0.4a 0.8 ± 0.7 0.9 ± 0.8
4(100) 4(100) 1.5 ± 0.6 1.8 ± 1.0 3.3 ± 1.0c
6(42.9) 7(50.0) 0.2 ± 0.6 0.8 ± 1.0 1.0 ± 1.2
8(88.8) 9(100)d 0.4 ± 0.5e 2.1 ±1.4d 2.6 ± 1.1d
ssed by Chi-square test, followed by pairwise analysis with Bonferroni
test for multiple comparison. aP < 0.01 vs. Group B, bP < 0.01 vs. Group A,
Figure 2 Global gene analysis in the glandular stomach of MNU-treated mice using oligonucleotide microarray. A: Number of genes
up- or down-regulated more than two-fold in the stomach of MNU-treated mice. In Venn’s diagram, the circles indicate up- (left) or down-regulated
(right) genes in the stomach of MNU-treated mice with H. pylori infection, high-salt diet or their combination. The shaded area represents the up- or
down-regulated genes more than two-fold only by the combination. B: Quantitative real-time RT-PCR analysis of three selected up-regulated genes
(Cd177, Reg3g, and Muc13) in the stomachs of MNU-treated mice. Expression levels of the genes in each sample were normalized by Gapdh as internal
control using ΔΔCT method. Relative expression levels were represented as the X-fold change relative to Group A (fixed as 1.0). Statistical analysis was
performed by the Kruskal-Wallis test for general analysis and Tukey test for multiple comparison. Bars, SE; *, P < 0.01 vs. Group A and < 0.05 vs.
Group C; †, P < 0.01 vs. Group C.
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fection (Group A, 61.9% and Group B, 100%), albeit with-
out statistical significance. The multiplicities of total
tumors in both H. pylori-infected groups (Group B, 3.3 ±
1.0 tumors/mouse and Group D, 2.6 ± 1.1) were markedly
higher than those in non-infected groups (Group A, 0.9 ±
0.8 and Group C, 1.0 ± 1.2) (P < 0.05). The multiplicity of
gastric adenocarcinoma in Group D (2.1 ± 1.4) was slightly
higher than that in Group B (1.8 ± 1.0) and significantly
increased over the Group C value (0.8 ± 1.0) (P < 0.05). In
contrast, the multiplicities of adenomas in Groups A and
D (0.1 ± 0.4 and 0.4 ± 0.5, respectively) were significantly
lower than in Group B (1.5 ± 0.6) (P < 0.05 and 0.01).Gene expression profiling in the glandular stomachs by
oligonucleotide microarray
With oligonucleotide microarrays, compared with the
non-infected and basal diet-treated group (Group A), 34
genes were up-regulated and 169 were down-regulatedmore than two-fold in H. pylori-infected mice (Group B),
56 up-regulated and 129 down-regulated in high-salt diet-
treated mice (Group C), and 69 up-regulated and 214
down-regulated in the combined group (Group D)
(Figure 2A). Taken together, as shown in Table 3, we
found that 35 genes were up-regulated and 31 genes were
down-regulated more than two-fold only by the combin-
ation of H. pylori infection and high-salt diet. In addition,
hierarchical clustering analysis was performed on the four
groups with a total of 303 qualified probes using the
complete-linkage clustering algorithm (Figure 3). Thirty-
one probes including Cd177, Reg3g and Muc13 were con-
firmed to be within a cluster of probes up-regulated only
in Group D. Subsequent analysis in the present study was
focused on these genes, because it was considered that the
genes in which expression was altered only in the com-
bined group might be associated with gastric carcinogen-
esis and progression in humans.
The entire results of this microarray analysis have
been submitted and are readily retrievable from the
Table 3 Regulated genes by combination of H. pylori infection and high-salt diet in mouse gastric mucosa
Accession no. Symbol Genes/proteins Fold changes
Up-regulated genes
XM_357640 Igk-V8 Immunoglobulin kappa chain variable 8 (V8) 14.4
XM_001472541 Ighg Immunoglobulin heavy chain (gamma polypeptide) 9.2
NM_026862 Cd177 CD177 antigen 7.3
NM_011260 Reg3g Regenerating islet-derived 3 gamma 6.1
NM_023137 Ubd Ubiquitin D 4.3
XM_144817 Igk-V34 Immunoglobulin kappa chain variable 34 (V34) 4.1
NM_007675 Ceacam10 Carcinoembryonic antigen-related cell adhesion molecule 10 3.7
NM_183322 Khdc1a KH domain containing 1A 3.3
NM_011475 Sprr2i Small proline-rich protein 2I 3.2
NM_175165 Tprg Transformation related protein 63 regulated 3.2
NM_175406 Atp6v0d2 ATPase, H+ transporting, lysosomal V0 subunit D2 3.0
NM_009703 Araf v-raf murine sarcoma 3611 viral oncogene homolog 2.6
NM_026822 Lce1b Late cornified envelope 1B 2.5
NM_016958 Krt14 Keratin 14 2.5
NM_212487 Krt78 Keratin 78 2.4
NM_009807 Casp1 Caspase 1 2.4
NM_146037 Kcnk13 Potassium channel, subfamily K, member 13 2.4
NM_019450 Il1f6 Interleukin 1 family, member 6 2.3
NM_008827 Pgf Placental growth factor 2.3
XM_893506 Klk12 Kallikrein related-peptidase 12 2.3
NM_016887 Cldn7 Claudin 7 2.3
NM_029360 Tm4sf5 Transmembrane 4 superfamily member 5 2.2
NM_172301 Ccnb1 Cyclin B1 2.2
NM_010739 Muc13 Mucin 13, epithelial transmembrane 2.2
NM_011165 Prl4a1 Prolactin family 4, subfamily a, member 1 2.2
NM_010162 Ext1 Exostoses (multiple) 1 2.2
NM_011704 Vnn1 Vanin 1 2.1
NM_011082 Pigr Polymeric immunoglobulin receptor 2.1
NM_007769 Dmbt1 Deleted in malignant brain tumors 1 2.1
NM_022984 Retn Resistin 2.1
NM_173037 Tmco 7 Transmembrane and coiled-coil domain 7 2.1
NM_009100 Rptn Repetin 2.1
NM_007630 Ccnb2 Cyclin B2 2.1
NM_001081060 Slc9a3 Solute carrier family 9 (sodium/hydrogen exchanger), member 3 2.0
NM_146588 Olfr1030 Olfactory receptor 1030 2.0
Down-regulated genes
NM_008753 Oaz1 Ornithine decarboxylase antizyme 1 0.31
NM_027126 Hfe2 Hemochromatosis type 2 (juvenile) (human homolog) 0.33
NM_053206 Magee2 Melanoma antigen, family E, 2 0.33
NM_010924 Nnmt Nicotinamide N-methyltransferase 0.41
NM_026260 Tctn3 Tectonic family member 3 0.41
NM_181039 Lphn1 Latrophilin 1 0.43
NM_008312 Htr2c 5-hydroxytryptamine (serotonin) receptor 2C 0.43
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Table 3 Regulated genes by combination of H. pylori infection and high-salt diet in mouse gastric mucosa (Continued)
NM_146667 Olfr740 Olfactory receptor 740 0.44
NM_007550 Blm Bloom syndrome homolog (human) 0.44
NM_011243 Rarb Retinoic acid receptor, beta 0.44
NM_184052 Igf1 Insulin-like growth factor 1 0.45
NM_013893 Reg3d Regenerating islet-derived 3 delta 0.46
NM_008645 Mug1 Murinoglobulin 1 0.46
NM_029550 Keg1 Kidney expressed gene 1 0.46
NM_019388 Cd86 CD86 antigen 0.46
NM_011316 Saa4 Serum amyloid A 4 0.47
NM_007811 Cyp26a1 Cytochrome P450, family 26, subfamily a, polypeptide 1 0.47
NM_011538 Tbx6 T-box 6 0.48
NM_011086 Pip5k3 Phosphatidylinositol-3-phospate/phosphatidylinositol 5-kinase, type III 0.48
NM_133723 Asph Aspartate-beta-hydroxylase 0.48
NM_001081390 Palld Palladin, cytoskeletal associated protein 0.48
NM_007858 Diap1 Diaphanous homolog 1 (Drosophila) 0.48
NM_053271 Rims2 Regulating synaptic membrane exocytosis 2 0.48
NM_153163 Cadps2 Ca2+−dependent activator protein for secretion 2 0.49
NM_007541 Bglap1 Bone gamma carboxyglutamate protein 1 0.49
NM_031871 Ghdc GH3 domain containing 0.49
NM_025545 Aptx Aprataxin 0.49
NM_177322 Agtr1a Angiotensin II receptor, type 1a 0.49
NM_026872 Ubap2 Ubiquitin-associated protein 2 0.49
NM_028045 Erv3 Endogenous retroviral sequence 3 0.49
NM_011641 Trp63 Transformation related protein 63 0.49
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(GEO) with the accession number GSE29444 (sample
number: GSM728857-60).
Quantitative real-time RT-PCR analysis of gene expression
profiles in MNU-treated mouse stomachs
Relative quantitative real-time RT-PCR analysis of three se-
lected up-regulated genes (Cd177, Reg3g, and Muc13) in
H. pylori-infected and high-salt diet-treated mice con-
firmed increased expression of Cd177 and Reg3g, as shown
in Figure 2B, with significant differences. Although expres-
sion level of Muc13 in Group D was higher than all other
groups, there was no statistical significance among them
(P = 0.0712 vs. Group C).
Immunohistochemical expression of CD177 in human
advanced gastric cancers and correlation with
clinicopathological factors
On immunohistochemical analysis of human gastric cancer
tissues, CD177 was observed not only in the membranes
and cytoplasms of infiltrated neutrophils, but also in gastric
cancer cells of both well- and poorly-differentiatedadenocarcinomas (Figure 4A). Cancer cells of signet-ring
cell type (2 cases) were negative for CD177. Among 55 gas-
tric cancer cases, moderate to strong expression of CD177
was observed in 33 (60.0%) (Table 4).
The follow-up period of the patients ranged from 9 to
606 weeks (median = 83 weeks). Five-year survival rates
for CD177-positive and negative were 39.4% and 18.2%,
respectively. From the Kaplan-Meier survival curve ana-
lysis, CD177-positive expression was associated with bet-
ter overall survival (P = 0.0294, log-rank test) (Figure 4B).
There was no statistically significant correlation of CD177
expression with age, histological classification, depth of in-
vasion, and lymph node metastasis (Table 4).
Multivariate analysis for overall survival of human gastric
cancer cases
Using the Cox proportional hazards model, multivariate
analysis of clinicopathological variables, including the
patient age, tumor histological classification, invasion
depth, lymph node metastasis, and CD177 expression
(Table 5), revealed the last to be an independent factor
for overall survival (P = 0.0323). Patient age and low
Figure 3 Hierarchical clustering analysis of four experimental groups of MNU-treated mice. Expression data from 303 qualified probes
(left). The four experimental groups were classified into two clusters (Groups A/C) and (Groups B/D) based on similarities in expression patterns.
Each row represents a probe and each column represents a experimental group (Groups A-D). As shown in the color bar, green indicates up-
regulation; red indicates down-regulation; and black indicates no change. Thirty-one probes constituted a cluster of probes up-regulated only in
Group D (right).
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with poor overall survival (P = 0.0439 and 0.0017, re-
spectively). Tumor invasion depth and lymph node me-
tastasis were not independent factors of gastric cancer
cases in the present study (P > 0.05).Figure 4 Immunohistochemistry for CD177 in human advanced gastr
Immunohistochemical analysis of CD177 expression in human gastric canc
gastric adenocarcinoma. CD177 expression is present only in infiltrating ne
differentiated (b) carcinoma are negative. Original magnification, ×100 (inse
CD177 in well-differentiated (c) or poorly-differentiated (d) gastric cancer ce
Kaplan-Meier cumulative survival curves for CD177 negative and positive gDiscussion
In the present study, we demonstrated that the mouse
model combined with H. pylori infection and high-salt
diet is a useful tool to investigate the detailed mecha-
nisms both of development and progression of gastricic cancer and correlation with overall survival rate. A:
er tissue. (a and b) Negative staining (none to weak) for CD177 in a
utrophils while neoplastic cells of well-differentiated (a) or poorly-
t, ×400). (c and d) Note positive (moderate to strong) expression for
lls. Original magnification, ×100 (inset, ×400). B: Comparison of
astric cancer cases.
Table 4 CD177 expression in gastric carcinomas and its correlation with clinicopathological factors
Case no. CD177 Over-expression P value‡
Positive Negative
Strong Moderate Weak None
Gastric adenocarcinomas 55 18 15 17 5
Age
Years (means ± SD) 55.3 ± 10.4 60.2 ± 8.13 59.8 ± 11.0 60.4 ± 13.0 0.5039
Histological classification
Well/moderately-differentiated type* 21 6 9 4 2 0.1904
Poorly-differentiated/Signet-ring cell type** 34 12 6 13 3
Depth of invasion†
T1-3 27 5 10 10 2 0.2011
T4 26 11 5 7 3
Lymph node metastasis
N0 6 1 2 2 1 0.7869
N1-3 49 17 13 15 4
* Lauren’s intestinal type, ** Lauren’s diffuse type, † Case number was reduced to fifty-three because the depth of invasion was not classified in two cases,
‡ ANOVA and Chi-square test were performed for age and other factors, respectively.
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have been developed under various conditions, including
H. pylori or H. felis infection, exposure to chemical car-
cinogens, and genetic modification [21,30]. Since H. pyl-
ori is known as a most closely-associated risk factor in
man, animal models with infection of the bacterium,
such as that utilizing Mongolian gerbils, are considered
to be particularly important to mimic the background of
human gastric carcinogenesis. On the other hand, there
is a consensus that gastric cancer is a multifactorial dis-
ease [31]. Epidemiological studies and animal experi-
ments have demonstrated that development of stomach
cancer is also associated with many other factors includ-
ing salt intake, alcohol drinking and cigarette, containing
a wide variety of chemical carcinogen. In the present
study, we attempted to mimic the gastric environment
of human high-risk group exposed to combination of H.
pylori infection, salt intake, and carcinogen.
As might be expected, there are both advantages and
disadvantages of Helicobacter-infected mouse models. In-
stability of cag pathogenicity islands (PAI), a particularly
important virulence factor of H. pylori, has been reported
in the mouse model using SS1 strain [32]. Multiplicity of
gastric tumors is difficult to examine in the gerbil model,Table 5 Multivariate analysis of prognostic factos in patients
Factors Hazard rat
CD177 expression (negative) 2.07
Age (year) 1.04
Histological type (poorly-differentiated) 4.06
Depth of invasion (high grade) 1.64
Lymph node metastasis (positive) 3.40because almost all of the stomach tumors in gerbils show
invasive growth into the lamina propria or muscle layer.
In the present study, our results demonstrated that H. pyl-
ori infection increased not only incidence but also multi-
plicity of gastric tumors in MNU-treated mice. Thus, the
mouse model presented here has advantages in respect to
investigate the multiplicity and tissue sampling for gene
expression analysis.
In this study, we focused on the genes in which the ex-
pression was regulated only in H. pylori-infection and
high-salt diet combined mice, which are expected to reflect
the background of human high-risk group, to explore ex-
amples which might be associated with tumor progression.
The two up-regulated genes selected, Cd177 and Reg3g
could be confirmed to exhibit significant over-expression
by relative quantitative RT-PCR. Expression level of Muc13
showed a tendency for increase with combination of H.
pylori and salt, although this was not statistically signifi-
cant. Muc13 is a recently identified gene encoding trans-
membrane mucin that is expressed in the stomach to
large intestine [33]. Shimamura et al. have reported that
overexpression of Muc13 is associated with differentiation
towards the intestinal (differentiated) type of human gastric
cancer [34]. In addition, the combined expression ofwith gastric cancer using Cox proportional hazard model
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prognostic indicator in several types of gastric cancer [35].
In the present study, all gastric tumors observed in MNU-
treated mice were histologically of differentiated type. The
REG protein family is also known to be associated with
gastric cancer development and Reg1α and Reg4 have been
suggested as prognostic markers for advanced stomach
cancers in man [36]. The present results indicate the possi-
bility that Reg3g is also involved with progression of stom-
ach tumor.
Immunohistochemical analysis of CD177 in advanced
gastric cancer specimens showed expression to be signifi-
cantly correlated with a good prognosis and survival rate
after surgery. Importantly, multivariate analysis with clini-
copathological factors as covariates further revealed high
expression to be an independent prognostic factor for over-
all survival, as along with patient’s age and histological clas-
sification. To our knowledge, the present study is the first
to provide evidence that high expression of CD177 is asso-
ciated with favorable prognosis in advanced gastric cancer.
CD177 is a member of the leukocyte antigen 6 (Ly-6)
gene superfamily, encoding two neutrophil-associated
proteins, NB1 and PRV-1 [37,38]. The NB1 glycoprotein
is typically expressed on a subpopulation of neutrophils,
located at plasma membranes and secondary granules.
Recent studies have demonstrated that CD177 is over-
expressed in neutrophils from 95% of patients with polycy-
themia vera and in half of patients with essential thrombo-
cythemia [37]. Gonda et al. have reported a microarray
analysis that Cd177 expression in whole gastric tissue of
H. felis-infected mice with mucosal dysplasia is reduced by
folic acid supplementation [39]. Because they compared
stage-matched groups to detect up- or down-regulated
genes only by treatment of folic acid, it is unclear if Cd177
expression is associated with gastritis or dysplasia. In our
microarray results, there were no significant differences in
expression of Ela2, which is a neutrophil-specific gene
[40], and histological degrees of neutrophil infiltration
were almost same among H. pylori-infected groups (data
not shown). Therefore, the up-regulation of Cd177 ob-
served in this study was considered to be caused not by in-
creased infiltration of neutrophils into the gastric mucosa
but by a change of gene expression in tumor cells. NB1 is
similar in structure to urokinase-type plasminogen activa-
tor receptor (uPAR), which is known to be associated with
cell adhesion and migration [37]. Thus, there is a possibil-
ity that CD177 also acts as a regulator of adhesion and mi-
gration of neoplastic cells in gastric tumor. Further studies
are needed to clarify the association between CD177 ex-
pression in gastric epithelial cells and tumor progression.
Conclusions
We demonstrated that the mouse model combined with
H. pylori infection and high-salt diet is suitable forinvestigation of global gene expression associated with gas-
tric tumor development and progression. Furthermore, our
results suggest that CD177 expression might be associated
with a favorable prognosis of gastric adenocarcinomas
in man.
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